View Latest Issue
According to a network meta-analysis and cost-per-responder (CPR) analysis presented at the recent Academy of Managed Care Pharmacy annual meeting, adalimumab was the most cost-effective biologic for the treatment of psoriatic arthritis (PsA) in terms of incremental CPR for 2 clinical efficacy measurements and at 2 time points, weeks 12 and 24.
Despite the high direct medical costs of treating systemic lupus erythematosus (SLE), opportunities exist for improving SLE treatment rates, treatment appropriateness, and referral to specialists, according to research presented at the Academy of Managed Care Pharmacy annual meeting.
In a study reported at the Academy of Managed Care Pharmacy annual meeting, adalimumab was found to have the lowest incremental cost per responder (CPR) and to be cost-saving, compared with the next most cost-effective option, etanercept, among the biologics approved by the US Food and Drug Administration (FDA) for treating ankylosing spondylitis (AS).
An analysis of data from 337 people with treatment-refractory ankylosing spondylitis (AS) indicated 88.1% received only one line of anti–tumor necrosis factor-α (anti-TNF-α) therapy while the remaining 11.9% switched to one or more anti-TNF-α agents.
There is an association between discontinuation of biologic therapy in patients with rheumatoid arthritis (RA) and using a lower number of disease-modifying antirheumatic drugs (DMARDs) or not using concomitant methotrexate.
How can the high cost of healthcare be spread among all stakeholders to produce the biggest patient-care bang for the buck?
As a physician with substantial income (or income potential), you will most likely be contacted by a number of individuals offering various types of financial products and services throughout your career.
Page 3 of 3
Results 21 - 27 of 27
  • Rheumatology Practice Management
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology